TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)
Brief Summary: An Implantable Cardioverter-Defibrillator (ICD) is a device implanted in a patient's chest to monitor the heart rhythm and deliver shocks to terminate potentially lethal arrhythmias when necessary. While ICDs reduce sudden cardiac death, patients with ICDs eventually die of heart failure or other diseases. As patients near the end of life, physiologic changes (intrinsic and extrinsic to the heart) may affect the cardiac conduction system, leading to more arrhythmias and increasing the frequency of shocks. Because ICD shocks can cause pain and anxiety and may not prolong a life of acceptable quality, it is appropriate to consider deactivating the shocking function of ICDs as patients' clinical status worsens and death is near. This will be a randomized controlled trial of a physician centered counseling and education intervention to improve clinician-patient communication about the management of ICDs.


Options:
A: Arm Label: communication lecture; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: communication lecture | Arm Label: lecture plus CD-ROM; Type: EXPERIMENTAL; Interventions: Behavioral: lecture plus CD-ROM | Intervention Type: BEHAVIORAL; Name: communication lecture; Assigned to Arm(s): communication lecture | Intervention Type: BEHAVIORAL; Name: lecture plus CD-ROM; Assigned to Arm(s): lecture plus CD-ROM
B: Arm Label: Supportive Information Team Group; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive Information Team Group | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supportive Information Team Group; Assigned to Arm(s): Supportive Information Team Group
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication, Behavioral: Systematic Pain Assessment and Treatment, Behavioral: Medication Review, Behavioral: Occupational therapy, Behavioral: Safety | Intervention Type: BEHAVIORAL; Name: Communication; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Systematic Pain Assessment and Treatment; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Medication Review; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Occupational therapy; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Safety; Assigned to Arm(s): Intervention
D: Arm Label: Communication training for cardiologists; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training for cardiologists. | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Communication training for cardiologists.; Assigned to Arm(s): Communication training for cardiologists | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medication Intervention in Transitional Care to Optimize Outcomes & Costs in CKD & ESRD
Brief Summary: Transitional care strategies focused on enhancing the accuracy and comprehensiveness of medication information transfer will lead to improved health outcomes among hospitalized patients with chronic kidney disease.


Options:
A: Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care for hospital discharge | Arm Label: intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Medication Information Transfer Intervention | Intervention Type: OTHER; Name: Medication Information Transfer Intervention; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Usual care for hospital discharge; Assigned to Arm(s): control
B: Arm Label: Motivational interview; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interview | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): Motivational interview
C: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Arm Label: Usual care + feedback of practice performance; Type: ACTIVE_COMPARATOR; Interventions: Other: Feedback of Performance | Arm Label: Usual care + feedback + health psychology intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Feedback of Performance + Health Psychology Informed Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: OTHER; Name: Feedback of Performance; Assigned to Arm(s): Usual care + feedback of practice performance | Intervention Type: OTHER; Name: Feedback of Performance + Health Psychology Informed Intervention; Assigned to Arm(s): Usual care + feedback + health psychology intervention
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medication Intervention in Transitional Care to Optimize Outcomes & Costs in CKD & ESRD
Brief Summary: Transitional care strategies focused on enhancing the accuracy and comprehensiveness of medication information transfer will lead to improved health outcomes among hospitalized patients with chronic kidney disease.


Options:
A: Arm Label: control group; Type: N/A; Interventions: N/A | Arm Label: Case management group; Type: N/A; Interventions: N/A
B: Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care for hospital discharge | Arm Label: intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Medication Information Transfer Intervention | Intervention Type: OTHER; Name: Medication Information Transfer Intervention; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Usual care for hospital discharge; Assigned to Arm(s): control
C: Arm Label: RASP; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical care plan, mostly based on the RASP | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care plan, mostly based on the RASP; Assigned to Arm(s): RASP
D: Arm Label: Application of STOPP/START criteria; Type: ACTIVE_COMPARATOR; Interventions: Other: Application of STOPP/START criteria | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Normal pharmaceutical care | Intervention Type: OTHER; Name: Application of STOPP/START criteria; Assigned to Arm(s): Application of STOPP/START criteria | Intervention Type: OTHER; Name: Normal pharmaceutical care; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial
Brief Summary: The purpose of this double blind, randomized and sham controlled study is to determine whether renal denervation in terms of catheter based ablation in the renal arteries is effective in lowering blood pressure in patients with treatment resistant hypertension. The blood pressure lowering effect will be evaluated by 24 hours ambulatory blood pressure measurement at baseline and after 1, 3 and 6 months of follow up. Secondary end point evaluation concerns hemodynamic measures using echocardiography, applanation tonometry and forearm plethysmography.


Options:
A: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen
B: Arm Label: Renal denervation; Type: N/A; Interventions: Device: Renal denervation using Symplicity Catheter system | Intervention Type: DEVICE; Name: Renal denervation using Symplicity Catheter system; Assigned to Arm(s): Renal denervation
C: Arm Label: Renal artery ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal artery ablation | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Procedure: Renal angiography | Intervention Type: PROCEDURE; Name: Renal artery ablation; Assigned to Arm(s): Renal artery ablation | Intervention Type: PROCEDURE; Name: Renal angiography; Assigned to Arm(s): Sham
D: Arm Label: Ultrasound Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: The Paradise® Renal Denervation Ultrasound System | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Device: Sham Procedure | Intervention Type: DEVICE; Name: The Paradise® Renal Denervation Ultrasound System; Assigned to Arm(s): Ultrasound Renal Denervation | Intervention Type: DEVICE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)
Brief Summary: This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospital costs.


Options:
A: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL
B: Arm Label: SKY0402; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl
C: Arm Label: IV morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL (bupivacaine liposome injectable suspension) | Intervention Type: DRUG; Name: IV morphine sulfate; Assigned to Arm(s): IV morphine sulfate | Intervention Type: DRUG; Name: EXPAREL (bupivacaine liposome injectable suspension); Assigned to Arm(s): EXPAREL
D: Arm Label: Morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine sulfate | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: bupivacaine liposome extended-release injectable suspension | Intervention Type: DRUG; Name: morphine sulfate; Assigned to Arm(s): Morphine sulfate | Intervention Type: DRUG; Name: bupivacaine liposome extended-release injectable suspension; Assigned to Arm(s): EXPAREL

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)
Brief Summary: This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospital costs.


Options:
A: Arm Label: IV morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL (bupivacaine liposome injectable suspension) | Intervention Type: DRUG; Name: IV morphine sulfate; Assigned to Arm(s): IV morphine sulfate | Intervention Type: DRUG; Name: EXPAREL (bupivacaine liposome injectable suspension); Assigned to Arm(s): EXPAREL
B: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402
C: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL
D: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)
Brief Summary: This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospital costs.


Options:
A: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402
B: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL
C: Arm Label: Bupivacaine HCl 105mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402 low dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 Middle dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 High dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl 105mg | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 High dose, SKY0402 Middle dose, SKY0402 low dose
D: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm
Brief Summary: Patients with advanced ovarian cancer (FIGO stage III C) and highly disseminated tumor will be randomized into two arms: primary debulking surgery followed by adjuvant chemotherapy vs. neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The primary end point is the evaluation and comparison of the surgical complications of primary surgery and IDS and the evaluation of the progression free survival (PFS)


Options:
A: Intervention Type: DRUG; Name: Neoadjuvant chemotherapy (Paclitaxel and Carboplatin); Assigned to Arm(s): N/A
B: Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX
C: Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery
D: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
Brief Summary: The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6 months in 9-14 years old healthy females.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
B: Arm Label: Cervarix 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Gardasil 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, Drug: Placebo | Arm Label: Gardasil 3 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 2 dose Group | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil 2 dose Group, Gardasil 3 dose Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 2 dose Group, Gardasil 2 dose Group
C: N/A
D: Arm Label: Arm A: QHPV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV) | Arm Label: Arm B: Placebo/QHPV; Type: OTHER; Interventions: Other: Placebo/QHPV | Intervention Type: BIOLOGICAL; Name: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV); Assigned to Arm(s): Arm A: QHPV | Intervention Type: OTHER; Name: Placebo/QHPV; Assigned to Arm(s): Arm B: Placebo/QHPV

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
Brief Summary: The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6 months in 9-14 years old healthy females.


Options:
A: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: CervarixTM | Arm Label: Placebo Group; Type: EXPERIMENTAL; Interventions: Other: Control | Intervention Type: BIOLOGICAL; Name: CervarixTM; Assigned to Arm(s): Cervarix Group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Placebo Group
D: Arm Label: Cervarix 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Gardasil 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, Drug: Placebo | Arm Label: Gardasil 3 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 2 dose Group | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil 2 dose Group, Gardasil 3 dose Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 2 dose Group, Gardasil 2 dose Group

Answer: D